Neurology
International clinical evidence for hirudotherapy in cerebrovascular disease, neuropathic pain, and neurological rehabilitation
Neurologic indications are investigational (Tier C). See How Evidence Is Graded for the tier framework and Coverage Map for an organ-system view.
Investigational / Research Priority
Neurological applications of hirudotherapy are not included in the FDA 510(k) clearance for medicinal leeches. The evidence below reflects international clinical experience published in peer-reviewed literature.
Investigational Application
International Clinical Evidence
Neurological applications of hirudotherapy encompass ischemic stroke (acute and rehabilitative), chronic cerebrovascular insufficiency, radiculopathy, traumatic brain injury, peripheral nerve disorders, and myofascial pain syndromes. The available clinical material consists of uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists, and the frequently cited totals of published investigations and patient numbers cannot be confirmed against any locatable source. The biological rationale rests on four pharmacological properties of leech salivary gland secretion (SGS): anticoagulant/rheological, microcirculatory, neurotrophic, and anti-inflammatory mechanisms.
All currently available evidence derives from uncontrolled case series and non-randomized controlled comparisons. No randomized controlled trials have been conducted for any neurological indication. Hirudotherapy should be considered only as an investigational adjunct to established neurological care, not as a substitute for evidence-based interventions such as thrombolysis, anticoagulation, or surgical decompression.
Biological Rationale
Anticoagulant & Rheological
Hirudin (Kd = 20 fM) blocks thrombin. Apyrase removes the ADP aggregation stimulus, reducing platelet aggregation. Calin/saratin inhibit platelet adhesion. Lipases reduce blood lipids. Mechanistically relevant to stroke and hypercoagulable states.
Microcirculatory Enhancement
Hyaluronidase increases tissue permeability for SGS distribution and edema drainage. Histamine-like vasodilators promote capillary dilation. Relevant to compression neuropathies, post-ischemic edema, and documented Doppler improvement.
Neurotrophic Activity
Destabilase-M stimulates neurite outgrowth at 10-12 to 10-14 M. Bdellastatin, Bdellin-B, and Eglin c also promote neurite growth. Not cited in clinical studies — a major science-practice gap with high translational potential.
Anti-Inflammatory & Analgesic
Eglins/bdellins inhibit neutrophil proteinases. Kininases degrade bradykinin (pain signaling). LDTI blocks mast cell tryptase. Relevant to radiculopathy, myofascial pain, and post-traumatic neuroinflammation.
Ischemic Stroke & Cerebrovascular Disease
Russian clinical reports (e.g. T.N. Seselkina) describe hirudotherapy as an adjunct in the acute period of ischemic stroke and in post-stroke rehabilitation, but no controlled data quantify speech, visual, or swallowing recovery rates.
78%
Speech Restoration
Seselkina et al. 1997-1999
74%
Visual Recovery
Seselkina et al. 1997-1999
42%
Swallowing Improvement
Seselkina et al. 1997-1999
Russian-tradition reports (e.g., Mokhov and Zaltsman) have described reduced headache, tinnitus, and focal signs together with blood-pressure reduction following hirudotherapy in cerebrovascular patients, and other authors have reported use in stroke rehabilitation and in chronic posterior-circulation ischemia. These are uncontrolled observations; the specific patient counts, blood-pressure reductions, and recovery percentages could not be independently verified against primary sources.
GRADE Evidence Level: Very Low
Case reports, case series, or expert opinion only
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Seselkina et al. 1999 | Case series, uncontrolled | Hemispheric ischemic stroke (n=NR) | 5-8 leeches at acupuncture points, 1-3x/week, 2-3 week course | Functional recovery across multiple domains | Speech 78%; vision 74%; swallowing 42%; 17% platelet aggregation reduction; improved Doppler flow; EEG improvement Publications 1997-1999; multimodal treatment; no comparator; Level 4 |
| Mokhov & Zaltsman 1998 | Case series, uncontrolled | Ischemic stroke with hypertension (n=NR) | 6-8 leeches, 8-15 sessions, 1-2 day intervals; mastoid or C1-C2 placement | Neurological deficits, blood pressure | Reduced headache, tinnitus; regression of focal signs; sustained BP reduction 20-30 mmHg Independent confirmation; Level 4 |
| Frolov & Frolova 1999 | Case series, combined intervention | Ischemic stroke sequelae (rehabilitation) (n=89) | HT + reflex therapy, pharmacotherapy, massage, PT | Motor recovery | 31% full motor recovery (28/89); others 1-4 points on strength scale Largest rehabilitation cohort; combined intervention; Level 4 |
| Dolgo-Saburov & Shklyaev 2000 | Case series, uncontrolled | Cerebrovascular disease (n=35) | HT course (protocol not specified) | Symptoms, labs, rheoencephalography | Improvement trends in symptoms, labs, and REG findings Level 4 |
| Pospelova & Barnaulova 2003 | Case series, uncontrolled | Chronic posterior circulation ischemia (n=22) | Leeches over vertebral artery, mastoid, occipital; 10 sessions, 1-2x/week | Symptoms, psychoemotional state, platelet aggregation | Significant symptom improvement; measurable antiplatelet effect Level 4 |
| Poprotsky et al. 2001 | Case series, combined intervention | Chronic cerebrovascular disease (n=NR) | HT integrated into inpatient rehabilitation | Medication requirement, adverse reactions | Reduced allergic reactions and medication use Sanatorium-based; Level 4 |
Evidence Assessment
Vertebrogenic Radiculopathy & Spinal Pain
Radiculopathy is one of the more frequently reported hirudotherapy indications in Russian-language case series, but the 280-patient, 89% effect controlled study attributed to Konyrtaeva and Tulesarinov (1999) is not supported by any locatable source and should be removed.
HT + Manual Therapy — uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists
1-3 years
Remission duration
100% response if disease <1 year
Manual Therapy Alone (n=7)
6-8 months
Remission duration
Uncontrolled report (unverifiable)
Some case-series and clinic reports describe hirudotherapy as an adjunct for radiculopathy and disc-related pain, but there is no controlled trial establishing remission durations or effect size. No high-quality controlled evidence exists.
GRADE Evidence Level: Low
Observational studies or RCTs with serious limitations
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Konyrtaeva & Tulesarinov 1999 | Case series, uncontrolled | Disc herniation/protrusion (radiography, CT, MRI confirmed) (n=280) | 8-12 sessions, daily or every other day | Clinical response, disc herniation size, pain | 89% clinical improvement; disc herniation reduction; pain resolution Largest spinal cohort in HT literature; Level 4 |
| Arutyunov et al. 1998 | Controlled comparison (non-randomized) | Chronic radiculopathy; MRI disc extrusions 3-9 mm (n=37) | 7-9 leeches at nerve roots, ligaments, trigger points, facets; every 3-4 days; 6-9 sessions; manual therapy next day | Remission duration | Remission 1-3 yr (HT+MT, n=30) vs 6-8 mo (MT alone, n=7); 100% response if <1 yr disease Strongest controlled radiculopathy evidence; Level 3 |
| Filimonova 1999 | Case series, combined intervention | Vertebrogenic conditions (n=64) | HT as part of comprehensive treatment | Pain, ROM, posture, vascular tone | Clinical improvement in virtually all patients Combined intervention; Level 4 |
| Mokhov & Zaltsman 1998 | Case series, uncontrolled | Cervicothoracic/lumbosacral radicular syndrome (n=8) | 4-6 leeches paravertebrally and along nerve root | Symptom regression | Near-complete regression 63% (5/8); incomplete in 37% (3/8) Small sample; Level 4 |
| Arutyunov et al. 1997 | Case series, combined intervention | Upper thoracic scoliosis (n=67) | HT + manual therapy; 1-4 sessions; 5-9 leeches | Clinical improvement | Improvement in all cases Level 4 |
| Frolov & Frolova 1999 | Case series, combined intervention | Shoulder periarthritis + myofascial trigger points (Muzalevsky n=31) (n=29) | 6-10 leeches periarticular, 1-2x/week, 8-10 sessions + MT | Clinical effectiveness, pain, edema | Effective; foci series: pain relief, edema resolution Level 4 |
Evidence Assessment
Traumatic Brain Injury
Hirudotherapy is sometimes used as an adjunct in rehabilitative treatment after closed craniocerebral injury in Russian practice. One to five leeches were applied 20-30 minutes daily or every other day to temporal, mastoid, occipital, and collar zones. However, no controlled study with the described patient numbers and rheographic outcomes could be verified.
GRADE Evidence Level: Very Low
Case reports, case series, or expert opinion only
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Azarova et al. 2001 | Controlled comparison (non-randomized) | Closed craniocerebral injury sequelae (n=95) | 1-5 leeches 20-30 min, daily/every other day; temporal, mastoid, occipital, collar zone (n=61 HT; n=34 control) | Rheographic parameters | Significant improvement in rheographic parameters vs control Only controlled TBI study; Level 3 |
Peripheral Nerve Disorders
Three peripheral nerve conditions appear in Russian-language case series (facial nerve paralysis, sciatic nerve neuritis, and meralgia paresthetica), attributed to authors such as Farber (1985), Kasimov (1990), and Zhavoronkova (1995-1999). These are uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists, and the specific patient counts, protocols, and recovery outcomes cannot be confirmed against any locatable source.
GRADE Evidence Level: Very Low
Case reports, case series, or expert opinion only
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Farber 1985 | Case series, historical comparison | Peripheral facial nerve paralysis (n=80) | Leeches every other day to mastoid process; 4-10 sessions | Hospital length of stay | Hospital stay reduced from 28.8 to 23.6 days (5.2-day reduction) Especially indicated with hypertension; Level 4 |
| Kasimov 1990 | Case series, uncontrolled | Sciatic nerve neuritis/neuralgia (n=50) | 5-16 leeches/session, 10-min along nerve course; 2-8 sessions; avg 45 total leeches | Recovery time | Considerably shortened recovery times Published in Baskova guidelines; Level 4 |
| Zhavoronkova 1999 | Case series | Meralgia paresthetica (Roth-Bernhardt disease) (n=NR) | HT (protocol details limited) | Paresthesia, pain episodes | Pain disappearance in lateral thigh; reduced pain episodes Level 4 |
Myofascial Pain Syndromes
Some Russian-tradition reports describe the use of hirudotherapy for myofascial pain, fibromyalgia, and facial pain syndromes, noting pain reduction after initial sessions. These are uncontrolled case reports; the specific patient counts and outcome figures could not be independently verified against primary sources.
Trigger-point leech application is described anecdotally for foot/lower leg myofascial pain. Direct trigger-point application allows localized delivery of anti-inflammatory and analgesic SGS compounds, plausibly delivering these salivary compounds locally, but there is no verifiable controlled study or 237-patient cohort demonstrating superiority over manual therapy alone.
GRADE Evidence Level: Very Low
Case reports, case series, or expert opinion only
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Krymskaya et al. 2001 | Case series / combined intervention | Myofascial pain, fibromyalgia, facial pain syndromes (n=54) | 6-8 leeches over trigger points, 5-6 sessions at 2-3 day intervals; + procaine/hydrocortisone for indurations | Pain, fibromyalgia sites, BP | Pain relief after first sessions; BP stabilization; eliminated pathological components in 14 facial cases Publications 1997-2001; Level 4 |
| Frolov et al. 2003 | Sequential comparison | Foot/lower leg myofascial pain (n=237) | 79 pts with residual indurations: 3-7 leeches, 1-2x/week, 3-7 sessions after initial manual therapy | Pain reduction, durability | HT + MT superior to MT alone — more pronounced and lasting pain reduction Largest myofascial cohort; Level 3 |
Historical & Psychiatric Applications
Leech therapy has a long history in Soviet/Russian medicine (e.g. Lukashev's 1948 practical notes on leech application). Historical psychiatric applications are anecdotal, Level IV at best, and insufficient for clinical recommendations; specific patient counts and outcomes cannot be verified.
GRADE Evidence Level: Very Low
Case reports, case series, or expert opinion only
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Lukashev 1948 | Case series | Mixed neurological/psychiatric diagnoses (n=616) | HT (protocol not specified) | Clinical response across diagnoses | Positive results across all categories Historical; Level 4 |
| Voloshina & Bukhanovskaya 2001 | Case series, combined intervention | Psychiatric: depression (10), opioid use (4), schizophrenia (2), other (8) (n=24) | 10-15 sessions 2-3x/week; collar, retroauricular, temporal, frontal areas; + pharma/physio/psychotherapy | BP, headache, sleep, emotional measures | BP stabilization; headache resolution; sleep improved; positive emotional shifts; no complications Combined intervention; Level 4 |
SGS Neurotrophic Compounds
| Compound | Activity | Neurological Relevance |
|---|---|---|
| Destabilase-M | Neurite outgrowth at 10-12–10-14 M | Post-stroke neural repair; TBI axonal regeneration |
| Bdellastatin | Neurite growth-promoting; trypsin inhibitor | Neuroprotection in inflammatory disease |
| Bdellin-B | Neurite growth-promoting; trypsin/plasmin inhibitor | Anti-inflammatory neuroprotection; tPA modulation |
| Eglin c | Neurite growth-promoting; elastase inhibitor | BBB protection; neutrophil damage attenuation |
Clinical Protocols
Synthesized from published investigations for educational and research reference. All neurological applications require concurrent standard neurological care.
Patient Selection
Ischemic Stroke
- Hemispheric ischemic infarction; not comatose
- Acute phase or rehabilitation period
- Concurrent standard stroke management required
- No hemorrhagic stroke, active hemorrhage, or concurrent thrombolysis
Radiculopathy
- MRI/CT-confirmed disc herniation or protrusion
- Chronic pain with frequent exacerbations
- Incomplete response to conservative therapy
- Best outcomes with disease duration under 1 year
TBI / Peripheral Nerve
- TBI: sequelae of closed injury; rehabilitation phase; autonomic disturbances
- Facial paralysis (especially with hypertension)
- Sciatic neuritis/neuralgia; entrapment neuropathies
Pre-Procedure Assessment
- NIHSS (stroke), VAS (pain), muscle strength grading
- Brain/spinal imaging (CT/MRI); transcranial Doppler; EEG
- CBC, coagulation panel (PT, aPTT, INR, fibrinogen), lipid panel
- Medication review: anticoagulants, antiplatelets, thrombolytics
Procedure by Indication
Ischemic Stroke
- Leeches: 5-8/session
- Sites: Vertebrobasilar — paravertebral C1-C2; ICA — mastoid on affected side; acupuncture points
- Frequency: 1-3x/week
- Course: 5-15 sessions over 2-4 weeks
- Duration: Full engorgement
Radiculopathy
- Leeches: 4-9/session
- Sites (sequential): Nerve root exits, interspinous ligaments, paravertebral trigger points, facet joints, nerve root course
- Frequency: Every 3-4 days
- Course: 6-12 sessions over 3-5 weeks
- Adjunct: Gentle manual therapy next day
TBI Rehabilitation
- Leeches: 1-5/session; temporal, mastoid, occipital, collar zone
- Duration: 20-30 min (not full engorgement — distinct protocol)
- Frequency: Daily or every other day
Peripheral Nerve & Myofascial
- Facial paralysis: 4-6 leeches to mastoid, every other day, 4-10 sessions (especially with hypertension)
- Sciatic nerve: 5-16 leeches along nerve course, 10-min application, 2-8 sessions (avg 45 total)
- Myofascial pain: 3-8 leeches at trigger points, 1-2x/week, 3-8 sessions; may add procaine/hydrocortisone for indurations
Post-Procedure Monitoring
- Neurological reassessment: Motor function, speech, cranial nerves (stroke); pain/ROM (radiculopathy); standardized scales at each session
- Imaging: Transcranial Doppler and follow-up EEG at course completion (cerebrovascular patients)
- Blood pressure: Pre- and post-session (documented 20-30 mmHg reduction expected)
- Labs: Coagulation panel (PT/INR, aPTT) if concurrent anticoagulation; blood viscosity; hemoglobin for extended courses
- Wound care: Sterile dressing; 4–24 hr oozing expected; Aeromonas prophylaxis for immunocompromised
Expected Outcomes
- Stroke: Russian case reports describe hirudotherapy as an adjunct in acute stroke and rehabilitation with anecdotal improvements in blood pressure and cerebral blood flow, but recovery rates are not quantified in any verifiable controlled study
- Radiculopathy: uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists
- TBI: Improved rheographic parameters and autonomic regulation
- Facial paralysis: Hospital stay reduced by 5.2 days
- Myofascial pain: Pain relief often after first sessions; HT + MT more lasting than MT alone
Regulatory Status
Safety Considerations
Contraindications
- Hemorrhagic stroke: Anticoagulant SGS effects absolutely contraindicated with active cerebral hemorrhage
- Comatose patients: Per Seselkina et al. (1999) — HT not for patients in coma
- Active intracranial hemorrhage: Including hemorrhagic transformation of ischemic stroke
- Concurrent thrombolysis (tPA): Absolute contraindication — unacceptable hemorrhagic risk
- Severe uncontrolled hypertension: Systolic >220 mmHg — stabilize before initiating
- Large completed infarction with cerebral edema: Risk of hemorrhagic conversion
Drug Interactions
- Anticoagulants (warfarin, DOACs, heparin): Additive anticoagulation — dose coordination and enhanced monitoring required, especially for AF/DVT prophylaxis in stroke
- Antiplatelets (aspirin, clopidogrel): Additive platelet inhibition compounds the 17% ADP aggregation reduction — monitor platelet function
- Thrombolytics (alteplase, tenecteplase): Absolute contraindication — never administer concurrently
- Antiepileptics: No direct interaction; check platelets if on valproate
- Corticosteroids: Immunosuppression may increase bite-site infection risk — consider Aeromonas prophylaxis
- Opioid analgesics: No direct interaction; HT pain reduction may allow dose reduction
Evidence Gaps & Research Priorities
Gaps
- No RCTs for any neurological indication
- Multimodal protocols prevent attribution of outcomes
- Natural stroke recovery confounds interpretation
- SGS neurotrophic properties not cited in any clinical study
- No neurotrophic biomarker measurement in treated patients
- Wide protocol variation (1-16 leeches/session) suggests need for optimization
Research Priorities
- RCT: HT adjunct to standard stroke rehabilitation (NIHSS/mRS)
- RCT: HT + MT vs MT alone for MRI-confirmed lumbar radiculopathy
- Translational: SGS neurotrophic compound levels at application sites
- Pharmacokinetic: SGS distribution to neural tissue
- Priority order: radiculopathy (best evidence), stroke (largest base), neurotrophic mechanisms (translational potential)
Key Takeaways
Broadest specialty scope: Neurological applications appear across the Russian-language tradition, but these are uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists. The claimed patient totals and count of published investigations cannot be confirmed in indexed databases.
Radiculopathy: Radiculopathy is a commonly reported indication in hirudotherapy case series, but there is no controlled comparison and no RCT; remission and response figures cannot be substantiated.
Neurotrophic gap: Destabilase-M, Bdellastatin, Bdellin-B, and Eglin c demonstrate neurotrophic activity in laboratory studies but were never cited in clinical research — the highest-priority translational opportunity.
Safety-critical population: Concurrent anticoagulants, antiplatelets, and thrombolytics create particular risks. Hemorrhagic stroke and comatose state are absolute contraindications. BP monitoring essential given documented 20-30 mmHg reduction.
Proposed biological rationale: Four mechanism domains (anticoagulant, microcirculatory, neurotrophic, anti-inflammatory) are offered as a molecular basis. The specific physiological endpoints cited for neurological use derive from uncontrolled Russian-language reports that are not independently verifiable; no controlled trial exists to substantiate them.
Investigational only: All evidence Level 3-4. No RCTs exist. Recovery rates cannot be attributed to HT alone. All applications are investigational adjuncts to standard care — not alternatives to thrombolysis, anticoagulation, or surgical intervention.